Comparative Pharmacology
Head-to-head clinical analysis: CAP PROFEN versus PREVACID NAPRAPAC 375 COPACKAGED.
Peer-Reviewed Evidence
Head-to-head clinical analysis: CAP PROFEN versus PREVACID NAPRAPAC 375 COPACKAGED.
CAP-PROFEN vs PREVACID NAPRAPAC 375 (COPACKAGED)
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
CAP-PROFEN is a nonsteroidal anti-inflammatory drug (NSAID) that inhibits cyclooxygenase-1 (COX-1) and cyclooxygenase-2 (COX-2) enzymes, reducing prostaglandin synthesis and resulting in anti-inflammatory, analgesic, and antipyretic effects.
Lansoprazole, a proton pump inhibitor, suppresses gastric acid secretion by inhibiting the gastric H+/K+-ATPase at the secretory surface of the gastric parietal cell. Naproxen, a nonsteroidal anti-inflammatory drug, inhibits cyclooxygenase (COX-1 and COX-2) reducing prostaglandin synthesis, which mediates inflammation, pain, and fever.
200-400 mg orally every 4-6 hours as needed; maximum 1200 mg/day.
One tablet (naproxen 375 mg / lansoprazole 15 mg) orally twice daily.
None Documented
None Documented
2-4 hours (terminal half-life); prolonged in elderly (up to 6 h) and renal impairment.
Naproxen: 12-17 hours (mean 14 hours); allows twice-daily dosing. Lansoprazole: 1.5-2 hours (fast metabolizers) to 3-4 hours (slow metabolizers); clinically negligible due to irreversibly binding to proton pumps.
Primarily renal (70-80% as unchanged drug and glucuronide conjugate), with 10-15% biliary/fecal. Less than 5% unchanged in urine.
Naproxen: Approximately 95% excreted in urine as unchanged naproxen (10%) and metabolites (~60% 6-O-desmethylnaproxen and conjugates); <5% in feces. Lansoprazole: Primarily metabolized in liver; metabolites excreted in urine (14-23%) and feces (~22%).
Category C
Category C
Opioid and NSAID Combination
Proton Pump Inhibitor/NSAID Combination